

# Is Baloxavir Marboxil the Answer to Treating Childhood Influenza?

Omer Shaikh<sup>1</sup>, Sharmeen Fatima<sup>2</sup>, Wardah Navaid<sup>2</sup>, Gulrukh Shaikh<sup>3</sup>, and Abdulqadir Nashwan<sup>4</sup>

<sup>1</sup>Ziauddin University Faculty of Medicine

<sup>2</sup>Dow University of Health Sciences

<sup>3</sup>Liaquat National Hospital and Medical College

<sup>4</sup>Hamad Medical Corporation

August 25, 2022

## Abstract

Influenza A and B are the most common causes of respiratory tract-restricted acute viral disease. Each year, it is estimated that around 16% of children aged 5 to 17 are hospitalized. Baloxavir Marboxil has the potential to be an innovative alternative to the existing standard of therapy for these individuals.

## Hosted file

Influenxa.docx available at <https://authorea.com/users/432390/articles/583326-is-baloxavir-marboxil-the-answer-to-treating-childhood-influenza>